Author:
Hersi Ahmad,Wyse D. George
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference23 articles.
1. Boriani G, Diemberger I, Bif. M, et al.: Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 2004, 64:2741–2762. A comprehensive review of the principles of and drugs used for pharmacologic cardioversion.
2. Roy D, Rowe BH, Stiell IG, et al.: A randomized, controlled trial of RSD 1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004, 44:2355–2361.
3. Miller MR, McNamara RL, Segal JB, et al.: Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm. J Fam Prac 2000, 49:1033–1046. A review of the Efficacy of currently available antiarrhythmic drugs used for the maintenance of sinus rhythm.
4. Singh BN, Singh SN, Reda DJ, et al.: Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) investigators. N Engl J Med 2005, 352:1861–1872.
5. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation. A report of the American Heart Association Task Force on Practice Guidelines and Policy Conferences (Committee of Develop Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with North American society of Pacing and Electrophysiology. Eur Heart J 2001, 22:1852–1923. This is the currently published version of the American College of Cardiology/American Heart Association/European Society of Cardiology guidelines for treatment of AF. The guidelines have been recently revised.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献